Management of refractory autoimmune hemolytic anemia via allogeneic stem cell transplantation

Rotenstein, Lisa S; Nathan, Ashwin S.; Ghobrial, Irène M.; Antin, Joseph H.; Parnes, Aric

doi:10.1038/bmt.2016.152

Cited by 1 publication

(1 citation statement)

References 14 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Autoimmune hematological diseases (AHDs) have been reported to occur more frequently than other autoimmune complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). [1][2][3][4][5][6][7][8] Autoimmune hematological diseases may affect a single lineage of blood cells, for example, autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP), or 2 and/or 3 lineages, for example, Evans syndrome. In these AHDs, AIHA is the most common with estimates of the incidence between 2% and 6% 7,[9][10][11] in recipients of allo-HSCT.…”

Section: Introductionmentioning

confidence: 99%

Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation in adults: A southern China multicenter experience

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

To investigate the incidence and risk factors as well as prognosis of autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (allo‐HSCT), a total of 1377 adult hematological malignancies at three institutions were enrolled in this study. The 3‐year cumulative incidence of AIHA was 2.2 ± 0.4%. Multivariate analysis showed that haploidentical donors (HRDs) and chronic graft vs host disease (cGVHD) were the independent risk factors for AIHA. Patients with AIHA treated initially with corticosteroids combined with cyclosporine A (CsA) had a higher complete response rate than those with corticosteroids monotherapy (66.7% vs 11.1%; P = .013). The 3‐year cumulative incidence of malignant diseases relapse was 4.4 ± 4.3% and 28.0 ± 1.3% (P = .013), treatment‐related mortality (TRM) was 8.9 ± 6.3% and 17.4 ± 1.2% (P = .431), disease‐free survival (DFS) was 56.1 ± 1.5% and 86.7 ± 7.2% (P = .011), and overall survival (OS) was 86.3 ± 7.4% and 64.1 ± 1.5% (P = .054), respectively, in the patients with AIHA and those without AIHA. Our results indicate that HRDs and cGVHD are risk factors for AIHA and corticosteroids combined with CsA are superior to corticosteroids as initial treatment for AIHA. Autoimmune hemolytic anemia does not contribute to increase TRM and could reduce the malignant diseases relapse and increase DFS.

show abstract

Section: Introductionmentioning

confidence: 99%

Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation in adults: A southern China multicenter experience

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

show abstract

Management of refractory autoimmune hemolytic anemia via allogeneic stem cell transplantation

Cited by 1 publication

References 14 publications

Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation in adults: A southern China multicenter experience

Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation in adults: A southern China multicenter experience

Contact Info

Product

Resources

About